Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics Inc (ARQT)
:ARQT
RESEARCH TOOLSreports
Holding ARQT?
Track your performance easily
ARQT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.11 - $16.20
Previous CloseN/A
Volume446.87K
Average Volume (3M)2.04M
Market Cap
$1.61B
Enterprise Value$1.03B
Total Cash (Recent Filing)$3.42M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Feb 25, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding117,044,590
10 Day Avg. Volume1,939,127
30 Day Avg. Volume2,037,185
Standard Deviation0.27
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.75
Price to Cash Flow (P/CF)-11.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit18.91
Enterprise Value/Ebitda-5.89
Forecast
1Y Price Target
$19.60Price Target Upside42.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Arcutis Biotherapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company is well positioned to finance the Zoryve commercialization as well as development of early-stage assets with liquidity of $329M.
Product DevelopmentZoryve should benefit from further FDA approvals, including Zoryve foam for scalp & body psoriasis and Zoryve cream for atopic dermatitis in children.
Revenue GrowthZoryve sustains momentum as Arcutis reports ~366% YoY Zoryve revenue growth in 4Q.
Bears Say
Market CompetitionCommercial success is not assured since dermatology remains a highly competitive segment of the market.
Prescription DeclineThe Zoryve franchise experienced a significant decrease in prescription growth, with a 25.6% drop in total prescriptions and a 30.5% decline in new prescriptions.
Product Concentration RiskCommercial success is not assured due to competition, product concentration risk, potential negative impact from oral therapies, and uncertainty in obtaining additional indications for Zoryve.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARQT FAQ
What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?
Arcutis Biotherapeutics Inc lowest stock price was $3.11 and its highest was $16.20 in the past 12 months.
What is Arcutis Biotherapeutics Inc’s market cap?
Arcutis Biotherapeutics Inc’s market cap is $1.61B.
When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?
Arcutis Biotherapeutics Inc’s upcoming earnings report date is Feb 25, 2025 which is in 38 days.
How were Arcutis Biotherapeutics Inc’s earnings last quarter?
Arcutis Biotherapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Arcutis Biotherapeutics Inc overvalued?
According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued.
Does Arcutis Biotherapeutics Inc pay dividends?
Arcutis Biotherapeutics Inc does not currently pay dividends.
What is Arcutis Biotherapeutics Inc’s EPS estimate?
Arcutis Biotherapeutics Inc’s EPS estimate is -0.26.
How many shares outstanding does Arcutis Biotherapeutics Inc have?
Arcutis Biotherapeutics Inc has 117,044,590 shares outstanding.
What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?
Arcutis Biotherapeutics Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 7.66%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?
Among the largest hedge funds holding Arcutis Biotherapeutics Inc’s share is Gilder Gagnon Howe & Co LLC.. It holds Arcutis Biotherapeutics Inc’s shares valued at 33M.
---
Arcutis Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.60 (42.55% Upside)
$19.60 (42.55% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 295.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
296.25%
12-Months-Change
Fundamentals
Return on Equity
-192.31%
Trailing 12-Months
Asset Growth
49.29%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
---
ARQT Company Deck
---
ARQT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased significant growth in ZORYVE portfolio sales and gross-to-net improvements, indicating a strong financial performance. While there were some challenges, such as delays in Medicare Part D coverage and minor hurricane impacts, the overall outlook remains positive with strong cash management and expansion in Medicaid coverage.Read More>---
ARQT Stock 12 Month Forecast
Average Price Target
$19.60
▲(42.55% Upside)
Technical Analysis
AnaptysBio
―
Ascendis Pharma
―
Blueprint Medicines
―
Vertex Pharmaceuticals
―
Immunovant
―
Seres Therapeutics
―
Best Analysts Covering ARQT
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+41.86%
reiterated a buy rating 5 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +41.86% per trade.
---